- Chinese regulators have approved an inhaled version of a COVID-19 vaccine developed by Tianjin-based CanSino Biologics Inc. ( OTCPK:CASBF ) as a booster dose, the company announced over the weekend.
- The vaccine branded as Convidecia Air allows the formation of an aerosol from a liquid using a nebulizer for inhalation through the mouth.
- Convidecia Air uses the same adenovirus vector platform as the company’s intramuscular COVID-19 vaccine Convidecia, CanSino ( OTCPK:CASBF ) said, adding that the vaccine introduces a non-invasive option for immunization.
- Data published in the medical journal The Lancet highlighted the strength of the humoral, cellular, and mucosal immunity generated by Convidecia Air to fight infection and spread of COVID-19.
- Read: Seeking Alpha contributor Bamboo Works argued after CanSino ( OTCPK:CASBF ) won the WHO nod for the Convidecia vaccine in May that the decision will offer “limited benefits for the company as the pandemic fades and other products are widely available.”
For further details see:
CanSino wins regulatory nod in China for inhaled COVID-19 shot